144-Hour Visa-Free Transit Unlocks Wonders of Yunnan: "Yunnan: A Many-Splendored Life" Awaits You
21.10.2024 03:00:00 CEST | Business Wire | Press release
With the expansion of China's 144-hour visa-free transit policy, Yunnan Province has opened its doors wider to international travelers, extending to include Kunming, Lijiang, Yuxi, Pu'er, Chuxiong, Dali, Xishuangbanna, Honghe, Wenshan, and nine other cities and prefectures. Travelers from 54 countries can enter Yunnan through Kunming Changshui International Airport, Lijiang Sanyi International Airport, and Mohan Railway Port by presenting valid international travel documents and onward tickets within 144 hours. This allows for a spontaneous Yunnan tour without cumbersome visa processes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241020373774/en/
Countries Eligible for the 144-Hour Visa-Free Transit Policy in Yunnan Province (Graphic: Business Wire)
"Yunnan: A Many-Splendored Life" is a lifestyle with fantastic nature and great ecosystems. Yunnan boasts three World Natural Heritage Sites – Three Parallel Rivers, Chengjiang Fossil Site, and Yunnan Stone Forest. Snow-capped plateaus stand alongside peaks and canyons, complemented by rivers, lakes, and forests, to create a magnificent scenery. Yunnan is known as a blooming "Spring City": camellias grace Dali, flamboyant flowers brighten Xishuangbanna, Ottelia acuminata sways on Lugu Lake, and winter cherry blossoms adorn Wuliang Mountain. Kunming Dounan Flower Market allows travelers to take a piece of Yunnan's spring home. Yunnan is also home to rare animal species like Yunnan snub-nosed monkeys, Asian elephants, and black-headed gulls.
"Yunnan: A Many-Splendored Life" is a lifestyle with profound culture. Yunnan boasts three World Cultural Heritage Sites – Lijiang Old Town, Honghe Hani Rice Terraces, and Jingmai Mountain Ancient Tea Forests in Pu'er, and eight National Famous Historical and Cultural Cities. Historical corridors like Southern Silk Road and Tea Horse Road reflect Yunnan's foreign trade and cultural exchanges. The Bai's Three-Course Tea, the Naxi's Dongba culture and pictographs, the Yi's Torch Festival, and the Dai's Water-Splashing Festival and Peacock Dance highlight its vast cultural legacy.
"Yunnan: A Many-Splendored Life" is a green and healthy lifestyle. Yunnan is an ideal destination for wellness tourism, outdoor activities, and international sports events, with lush mountains, clear waters, and spring-like climate year-round. Eco-friendly products, including Yunnan's flowers, tea, fruits, vegetables, medicinal herbs, and coffee, along with dishes like Mushroom feasts, Yunnan ham, cross-bridge rice noodles, flower cakes, and steam pot chicken, create unforgettable memories.
Yunnan offers boundless natural beauty, a warm living atmosphere, and a healthy lifestyle. As the 144-hour visa-free travelers swarm in, Yunnan will extend greater hospitality and invite them to experience its unique charm and beauty.
Video link:
https://youtu.be/IIdperTx2EA?si=KsT_M88yNRHwJe26
View source version on businesswire.com: https://www.businesswire.com/news/home/20241020373774/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom